Nephron Clinical Practice

Original Paper

Catheter-Related Bacteremia in Hemodialysis: Which Preventive Measures to Take?

Silva J.a · e Costa T.a · Baptista A.b · Ramos A.a · Ponce P.a

Author affiliations

Departments of Nephrology,aHospital Garcia de Orta, Almada, and bHospital Distrital de Faro, Faro, Portugal

Keywords: Catheter-related infectionHemodialysisVascular access

Related Articles for ""
Nephron Clin Pract 2008;110:c251
https://doi.org/10.1159/000167873

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 25, 2008
Accepted: August 26, 2008
Published online: October 31, 2008
Issue release date: November 2008

Number of Print Pages: 1
Number of Figures: 1
Number of Tables: 5


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Abstract

Background: The use of tunneled hemodialysis catheters as definitive vascular access is becoming increasingly more widespread, reaching 25% of all dialysis patients in some countries. The rate of infectious morbidity and mortality is much higher when catheters are used than when patients are dialyzed through grafts or native fistulas, and it is generally agreed that implementing appropriate preventive measures would do more to lower its incidence. Methods: A prospective, randomized, open-label, long-term follow-up clinical trial was conducted to compare the efficacy of dressing the exit site with antibiotic ointment (AO) versus catheter antimicrobial locking (AL) in preventing catheter-related bacteremia (CRB), both associated with strict standard precautions and appropriate catheter care. A total of 141 tunneled catheters, newly implanted in 116 consecutive patients, were followed during a 2-year period. Patients were randomly distributed into one of three arms, with group A receiving AO prophylaxis, group B treated with a heparin + gentamicin (5.2 mg/ml) lock (AL) and group C receiving both AO and AL prophylaxis. Results: Group A had a significantly lower infection-free time survival curve (p < 0.02, Kaplan-Meier) with a catheter survival of 103.9 days and a significantly higher number of CRB (9 episodes, p < 0.02, χ2). Group B had 130.7 mean infection-free days and 1 episode of CRB. Group C had 127.3 mean infection-free days and 5 episodes of CRB. No toxicity or other adverse events were observed during this 2-year period, and the efficacy of the preventive measures remained stable throughout. Conclusion: Antimicrobial lock is superior to AO as a CRB preventive measure. The use of lock and ointment in the same catheter was not associated with additive effects.

© 2008 S. Karger AG, Basel



Related Articles:

References

  1. Kinney R: 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006;48:S1–S106.
    External Resources
  2. Ackad A, Simonian G, Steel K, et al: A journey in reversing practice patterns: a multidisciplinary experience in implementing DOQI guidelines for vascular access. Nephrol Dial Transplant 2005;20:1450–1455.
    External Resources
  3. Rayner HC, Besarab A, Brown WW, Disney A, Satio A, Pisoni RL: Vascular access results from the Outcomes and Practice Pattern Study (DOPPS): Performance against Kidney Disease Outcomes Quality Initiative(K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004;44(suppl 3):S22–S26.
    External Resources
  4. Tokars JI, Miller ER, Alter MJ, Arduino MJ: National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002;15:162–171.
    External Resources
  5. Schwab SJ, Beathard GA: The haemodialysis catheter conundrum: hate living with them but can’t live without them. Kidney Int 1999;56:1–17.
    External Resources
  6. Reddan D, Klassen P, Frankenfield DN, et al: National profile of practice patterns for haemodialysis vascular access in the United States. J Am Soc Nephrol 2002;13:2117–2124.
    External Resources
  7. Troidle L, Eisen T, Finkelstein FO: Why do so many patients have a dialysis catheter and not A-V fistulae or grafts? Proc 24th Annu Dial Conf, San Antonio, February 2004.
  8. Allon M, Robbin ML: Increasing A-V fistulas in haemodialysis patients: problems and solutions. Kidney Int 2002;62:1109–1112.
    External Resources
  9. Tokars J, Miller E, Stein G: New national surveillance system for haemodialysis-associated infections: initial results. Am J Infect Control 2002;30:288–295.
    External Resources
  10. Ishani A, Collins A, Herzog C, et al: Septicemia, access and cardiovascular disease in dialysis patients: The USRDS Wave 2 Study. Kidney Int 2005;68:311–318.
    External Resources
  11. Foley R, Guo H, Snyder J, et al: Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 2004;15:1038–1045.
    External Resources
  12. Reed S, Friedman J, Engemann J, et al: Costs and outcomes among haemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteraemia. Infect Control Hosp Epidemiol 2005;26:175–183.
    External Resources
  13. Johnson DW, MacGinley R, Kay TD, et al: A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002;17:1802–1807.
    External Resources
  14. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J: Haemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 2003;13:169–179.
    External Resources
  15. McIntyre CW, Hulme LJ, Taal M, Fluck R: Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004;66:801–805.
    External Resources
  16. Nori US, Manoharan A, Yee J, Besarab A: Comparison of low dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter related bacteraemia. Am J Kid Dis 2006;48:596–605.
    External Resources
  17. Betjes MGH, van Agteren M: Prevention of dialysis catheter related sepsis with a citrate-taurolidine containing lock solution. Nephrol Dial Transplant 2004;19:1546–1551.
    External Resources
  18. Allon M: Prophylaxis against dialysis related catheter bacteraemia with a novel antimicrobial lock solution. Clin Infec Dis 2003;36:1539–1544.
    External Resources
  19. Dogra GK, Herson H, Hutchinson B, et al: Prevention of tunneled hemodialysis catheter-related infections using catheter restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002;13:2133–2139.
    External Resources
  20. Maki DG, Stolz SM, Wheeler S, Mermel LA: Prevention of central venous catheter related bloodstream infection by use of antiseptic-impregnated catheter. Ann Intern Med 1997;127:257–266.
    External Resources
  21. Sitges-Serra A, Linares J, Garau J: Catheter sepsis: the clue is the hub. Surgery 1985;97:356–357.
  22. Haimi-Cohen Y, Husain N, Meenan H, Karayalcin G, Lehrer M, Rubin LG: Vancomycin and Ceftazidine bioactivities persists for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections using antibiotic lock technique. Antimicrob Agents Chemother 2001;45:1565–1567.
    External Resources
  23. Krishnasami Z, Carlton D, Bimbo L, et al: Management of haemodialysis catheter related bacteraemia with an adjunctive antibiotic lock solution. Kidney Int 2002;61:1136–1142.
    External Resources
  24. Anthony TU, Rubin LG: Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob Agents Chemother 1999;43:2074–2076.
    External Resources
  25. Pearson ML, Hierholzer WJJ, Garner JS, et al: Guideline for prevention of intravascular device-related infection. I. Intravascular device-relate infections: an overview. Am J Infect Control 1996;24:262–277.
    External Resources
  26. Maki DG: Pathogenesis, prevention and management of infections due to intravascular devices used for infusion therapy; in Bisno AL, Waldwogel FA (eds): Infections Associated with Indwelling Medical Devices. Washington, American Society for Microbiology, 1989, pp 161–177.
  27. Linares J, Sitges-Serra A, Garau J, Perez JL, Martin R: Pathogenesis of catheter sepsis: a prospective study with quantitative and semi-quantitative cultures of catheter hub and segments. J Clin Microbiol 1985;21:357–360.
    External Resources
  28. Maki DG, Ringer M, Alvarado CJ: Prospective randomized trial of povidone-iodine, alcohol and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991;338:339–343.
    External Resources
  29. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN: Risk of bacteraemia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int 2000;58:2543–2545.
    External Resources
  30. Beathard GA: Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999;10:1045–1049.
    External Resources
  31. Donlan RM: Biofilm formation: a clinically relevant microbiologic process. Clin Infect Dis 2001;33:1387–1392.
    External Resources
  32. Donlan RM: Biofilms: microbiological life on surfaces. Emerg Infect Dis 2002;8:881–890.
    External Resources
  33. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318–1322.
    External Resources
  34. Raad I, Costerton JW, Sabharwal U, Sacilowsky M, Anaissie E, Bodey GP: Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonisation and duration of placement. J Infect Dis 1993;168:400–407.
    External Resources
  35. Anaissie E, Samonis G, Kontoyiannis D, et al: Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections. Eur J Clin Microb Infect Dis 1995;4:134–137.
    External Resources
  36. Ponce P, Cruz J, Ferreira A, Oliveira C, Vinhas J, Silva G, Pina E: A prospective study on incidence of bacterial infections in Portuguese dialysis units. Nephron Clin Pract 2007;107:c133–c138.
    External Resources
  37. Weijmer MC, Van den Dorpel A, Van de Ven PJ, ter Wee PM, Van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer MA, Siegert CE, Stas KJ: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in HD patients. J Am Soc Nephrol 2005;16:2769– 2777.
    External Resources
  38. Saxena A, Panhotra B, Sundaram D, et al: Tunneled catheters outcome optimization among diabetics on dialysis through antibiotic lock technique. Kidney Int 2006;70:1629–1635.
    External Resources
  39. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB: Catheter-related bacteraemia and outcome of catheter attempted salvage in patients undergoing haemodialysis. Ann Intern Med 1997;127:275–280.
    External Resources
  40. Feeley T, Copley A, Bleyer AJ: Catheter lock solutions to prevent bloodstream infections in high-risk hemodialysis patients. Am J Nephrol 2007;27:24–29.
    External Resources
  41. US Food and Drug Administration: FDA issues warning on Tricitrasol dialysis anticoagulant. FDA Talk paper. Rockville, US Department of Health and Human Services, 2000. http://www.fda.gov/bbs/topics/ANSWERS/ANS01009.html.
  42. Allon M: Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 2004;44:779–791.
    External Resources
  43. Quarello F, Forneris G, Borca M, Pozzato M: Do central venous catheters have advantages over arteriovenous fistulas or grafts? J Nephrol 2006;19:265–279.
    External Resources
  44. Bleyer A: Use of antimicrobial catheter lock solutions to prevent catheter-related bacteremia. Clin J Am Soc Nephrol 2007;2:1073–1078.
    External Resources
  45. Zhang P, Zhang W, He Q, et al: A randomized controlled study on prevention of cuffed-tunneled catheter-related bacteraemia with gentamicin-heparin lock solution. J Am Soc Nephrol 2006;17:SA-PO073.
  46. Schwab SJ, Weiss MA, Rushton F, et al: Multicenter clinical trial results with the Lifesite hemodialysis access system. Kidney Int 2002;62:1026–1033.
    External Resources
  47. Churchill DN, Taylor DW, Cook RJ, Laplante P, Barre P, Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H, McKenzie JK, Muirhead N, Parfrey PS, Posen GA, Slaughter D, Ulan RA, Werb R: Canadian hemodialysis morbidity study. Am J Kidney Dis 1992;19:214–234.
    External Resources
  48. Minga TE, Flanagan KH, Allon M: Clinical consequences of infected arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2001;38:975–978.
    External Resources
  49. Poole CV, Carlton D, Bimbo L, Allon M: Treatment of catheter related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant 2004;19:1237–1244.
    External Resources
  50. Stevenson KB, Hannah EL, Lowder CA, Adcox MG, Davidson RL, Mallea MC, Narasimhan N, Wagnild JP: Epidemiology of haemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 2002;39:549–555.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 25, 2008
Accepted: August 26, 2008
Published online: October 31, 2008
Issue release date: November 2008

Number of Print Pages: 1
Number of Figures: 1
Number of Tables: 5


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2008, Vol.110, No. 4

November 2008

Article

Recommend This
TOP